Compare Abeona Therapeutics Inc (ABEO) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Marathon Petroleum Corp — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Marathon Petroleum Corp trades at $275.58 (market cap $77.75B). The key difference: Marathon Petroleum Corp is far larger — about 208.3× Abeona Therapeutics Inc's market cap, and Marathon Petroleum Corp pays a 1.47% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MPC | |
|---|---|---|
Market Cap | $373.32M | $77.75B |
Sector | Health | Energy |
52-Week High | $7.23 | $268.99 |
52-Week Low | $4.17 | $158.59 |
Enterprise Value | $228.22M | $109.93B |
Dividend Yield | — | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Marathon Petroleum (MPC) trades at $266.33, showing minimal daily movement (-0.01%) but maintaining strong momentum with a 52% gain over the past six months. The stock demonstrates robust profitability with ROE of 27.92% and net income margin of 3.42%, supported by favorable refining margins from global supply disruptions. Recent earnings show mixed performance with Q3 2025 missing estimates but Q1 2026 beating expectations by 123%.
MPC presents a compelling investment case with attractive valuation (P/E 17.71, P/S 0.6) and strong analyst support (76% buy ratings). However, declining revenue trends from $177.5B in 2022 to $132.7B in 2025 and rising debt-to-asset ratio to 42.59% warrant caution. The upcoming Q2 2026 earnings on August 4th will be critical for validating the current bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
